The global nerve repair and regeneration market size was valued at USD 7.93 billion in 2018 and is projected to expand at a CAGR of 10.7% over the forecast period. Rising cases of neurological disorders and strong product pipeline by the major companies are the key factors driving the market. Improved treatment efficiency for neurological disorders due to several technological advancements is also likely to contribute to the market growth.
In March 2016, Baxter completed the CE marking, the indication for marketing of ‘HEMOPATCH’ the ready-to-use surgical patch in the European market. This patch was approved for use as a hemostatic device to prevent loss of blood or any other body fluid and during traumatic injuries of the brain, CNS, or other body parts that result in shrinkage of dura mater.
Furthermore, availability of a number of therapies for treating various Central Nervous System (CNS) disorders, such as Parkinson’s disease and Alzheimer’s, and increasing scope of applications are further expected to boost the market growth over the forecast period. According to the World Health Organization (WHO), in 2018, 326 million people experienced migraine pain and 24 million were suffering from Alzheimer's disease.
Increasing awareness, environmental influence, lifestyle, genetics, nutrition, and physical injuries are some of the factors that can cause such disorders.
In 2015, a report presented in the annual meeting of the American Society for Surgery of the Hand (ASSH) stated that the processed nerve allograft used in the treatment of patients with upper extremity nerve impairments may lead to the restoration of motor and sensory nerve functions. Patients treated with a PNA allograft (Avance Nerve Graft, AxoGen) exhibited recovery of motor function and sensory nerve function in 75% and 85% of the patients, respectively.
Based on product, the market has been classified into biomaterials and neurostimulation & neuromodulation devices. The latter segment is further sub-segmented into Deep Brain Stimulation (DBS), Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Sacral Nerve Stimulation (SNS), and Gastric Electric Stimulation (GES) Devices.
Neurostimulation and neuromodulation devices was the largest product segment in 2018 and SCS was the largest sub-segment that accounted for a market share of over 40.0% in 2018. Large number of commercially available spinal cord products and wide range of applications were the factors responsible for the dominance of the segment.
Investments by key companies to develop more effective devices is likely to propel the market in coming years. For instance, in May 2016, Precision Montage MRI Spinal Cord Stimulator System (Boston Scientific) received the FDA approval. The company reported that their system provides 70% more relief from back pain.
Biomaterials segment is anticipated to expand at the fastest CAGR from 2019 to 2026 due to technological advancements, wide range of applications, government funding for innovations, and biocompatibility. Advanced products, such as biodegradable polymers, are expected to enhance spinal stabilization, healing of fractures, and reduce hospitalization.
Based on surgery, the market is divided into direct nerve repair or neurorrhaphy, nerve grafting, stem cell therapy, and neurostimulation & neuromodulation surgery. Neurostimulation & neuromodulation surgery held the largest market share of around 39.0% in 2018. However, stem cell therapy is expected to witness the fastest CAGR over the forecast years. Various government initiatives and approvals to conduct clinical trials of biomaterials are anticipated to boost the market. There are approximately 570 clinics in U.S. providing stem cell therapies and the number is expected to rise, thereby augmenting segment growth.
Expected commercialization of the products in coming years due to investments by companies and research institute is also anticipated to boost the market growth. For instance, in June 2016, Axonics Modulation Technologies was granted CE mark approval in European Union for its sacral nerve modulation system. The company has planned to commercialize it after a follow-up post-market clinical study.
Neurostimulation & neuromodulation surgery accounted for the largest share of the market in 2018 due to the availability of several products and technological advancement to reduce chronic pain. For instance, in April 2016, St. Jude launched Axium Neurostimulator System in U.S. and approved the implants for Dorsal Root Ganglion (DRG). The system reduces the chronic pain for complex regional pain syndrome I and II patients, which could not be achieved through traditional SCS system.
In 2018, North America led the market owing to increased incidence of neural disorders and supportive health insurance coverage scenario in the region. Availability of technologically advanced devices owing to the presence of major market players is also a major factor for the dominance of this region. For instance, in February 2016, Medtronic plc launched Reclaim DBS therapy for the treatment of Obsessive-Compulsive Disorder (OCD). Furthermore, Boston Scientific’s Precision Montage MRI-safe SCS, which is used for chronic pain, received FDA approval in May 2016.
Asia Pacific is the fastest-growing region due to the increasing target population base, rising awareness among patients, supportive government initiatives, presence of unmet medical needs, and advent of innovative technologies.
China, India, Japan, Australia, and Singapore are the major countries contributing to the region’s growth. In December 2015, the Australian Therapeutics Good Administration (TGA) approved clinical trials for the treatment method testing based on human parthenogenetic stem cells (ISC-hpNSC) in patients suffering from Parkinson’s disease. This approval is anticipated to drive the stem cells therapy market in the region.
Key companies are AxoGen, Inc.; Stryker Corporation; St. Jude Medical, Inc.; Baxter International, Inc.; Polyganics B.V.; Boston Scientific, Inc.; Integra Lifesciences Corporation; Cyberonics, Inc.; and Medtronic plc. The industry contributors have a broad product pipeline for neurological disorders. Market players are in a process of introducing advanced products to improve treatment efficiency, in turn, capturing a higher market share. For Instance, in January 2018, Boston Scientific Corporation announced positive results from the randomized controlled trial - WHISPER.
The WHISPER data demonstrates that patients who are given both paresthesia-based SCS and sub-perception, achieve superior outcomes. In June 2016, St Jude Medical launched direction DBS lead and Infinity DBS system to support treatments pertaining to movement disorders. It is designed with the aim of enabling Apple mobile devices to be used as wireless controllers with the help of Bluetooth connection and is the only upgradable DBS system for disorders, such as tremor, dystonia, and Parkinson’s disease.
In November 2017, AxoGen advanced the nerve repair platform at their annual day. In addition to the already existing portfolio for upper extremity trauma, oral & maxillofacial procedures, and carpal & cubital tunnel revision; the company has added Breast reconstruction neurotization and surgical management of pain to their portfolio.
Base year for estimation
Actual estimates/Historical data
2015 - 2017
2019 - 2026
Revenue in USD Million and CAGR from 2019 to 2026
North America, Europe, Asia Pacific, Latin America, and MEA
U.S., Canada, U.K., Germany, France, Italy, Spain, Japan, China, India, Australia, South Korea, Brazil, Mexico, Colombia, South Africa, Saudi Arabia, & UAE
Revenue forecast, company share, competitive landscape, growth factors & trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the global nerve repair and regeneration market report on the basis of product, surgery, and region:
Product Outlook (Revenue, USD Million, 2015 - 2026)
Neurostimulation and Neuromodulation Devices
Spinal Cord Stimulation Devices
Deep Brain Stimulation Devices
Sacral Nerve Stimulation Devices
Vagus Nerve Stimulation Devices
Gastric Electric Stimulation Devices
Surgery Outlook (Revenue, USD Million, 2015 - 2026)
Direct Nerve Repair/Neurorrhaphy
Stem Cell Therapy
Neurostimulation and Neuromodulation Surgeries
Regional Outlook (Revenue, USD Million, 2015 - 2026)
Middle East & Africa
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.